Moderna 2022 Priorities and Capital Allocation
Moderna's Respiratory Vaccines (Pipeline 1/3)
Modality
Program
mRNA-1273.351
COVID-19 vaccine
Adults
mRNA-1273.213
mRNA-1273.529
ID #
mRNA-1273/SpikevaxⓇ
mRNA-1273.617
mRNA-1273.211
Beta variant
Delta variant
Beta variant + wild-type
Beta+Delta variant
Preclinical
development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Omicron variant
Worldwide
mRNA-1273.214
Omicron variant + wild-type
Worldwide
mRNA-1283
Next generation (2-5 °C)
Worldwide
mRNA-1010
Phase 3 prep
Worldwide
mRNA-1011
Worldwide
Flu vaccine
mRNA-1012
Worldwide
mRNA-1020
Worldwide
mRNA-1030
Worldwide
Older adults RSV vaccine
mRNA-1345
Worldwide
COVID+ Flu vaccine
mRNA-1073
Worldwide
Adolescents
& Pediatrics
COVID + Flu + RSV vaccine
Endemic HCOV vaccine
COVID-19 vaccine (adolescents)
COVID-19 vaccine (pediatrics)
Pediatric RSV vaccine
mRNA-1230
Worldwide
mRNA-1287
Worldwide
mRNA-1273
TeenCOVE
Worldwide
mRNA-1273
KidCOVE
Worldwide
mRNA-1345
Worldwide
Pediatric hMPV + PIV3 vaccine
mRNA-1653
Worldwide
Pediatric RSV + hM PV vaccine
mRNA-1365
Worldwide
Slide 40
modernaView entire presentation